IDEXX Laboratories, Inc. (IDXX): Price and Financial Metrics
IDEXX Laboratories, Inc. (IDXX)
Today's Latest Price: $384.83 USD
Updated Aug 12 4:00pm
Add IDXX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 132 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
IDXX Stock Summary
- IDXX has a market capitalization of $31,813,000,838 -- more than approximately 93.96% of US stocks.
- Idexx Laboratories Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 96.22% of US listed stocks.
- Price to trailing twelve month operating cash flow for IDXX is currently 60.75, higher than 94.42% of US stocks with positive operating cash flow.
- If you're looking for stocks that are quantitatively similar to Idexx Laboratories Inc, a group of peers worth examining would be CFMS, CLX, MTD, PII, and RMTI.
- IDXX's SEC filings can be seen here. And to visit Idexx Laboratories Inc's official web site, go to www.idexx.com.
IDXX Stock Price Chart Technical Analysis Charts
IDXX Price/Volume Stats
| Current price | $384.83 | 52-week high | $407.86 |
| Prev. close | $374.03 | 52-week low | $168.65 |
| Day low | $375.02 | Volume | 444,192 |
| Day high | $387.84 | Avg. volume | 598,046 |
| 50-day MA | $343.03 | Dividend yield | N/A |
| 200-day MA | $284.56 | Market Cap | 32.73B |
IDEXX Laboratories, Inc. (IDXX) Company Bio
IDEXX Laboratories develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company was founded in 1983 and is based in Westbrook, Maine.
IDXX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $384.83 | $56.86 | -85% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Idexx Laboratories Inc. To summarize, we found that Idexx Laboratories Inc ranked in the 15th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 84.83%. The most interesting components of our discounted cash flow analysis for Idexx Laboratories Inc ended up being:
- The company's debt burden, as measured by earnings divided by interest payments, is 18.74 -- which is good for besting 82.83% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet reveals debt to be 3% of the company's capital (with equity being the remaining amount). Approximately just 11.05% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- IDXX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 48.44% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -85% |
| 1% | -85% |
| 2% | -85% |
| 3% | -85% |
| 4% | -85% |
| 5% | -84% |
Want more companies with a valuation profile/forecast similar to that of Idexx Laboratories Inc? See ABMC, COO, NUVA, BSX, and ELAN.
Loading social stream, please wait...